Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.28, $0.05 better than the analyst estimate of $0.23. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $80.56 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.